Comparative Pharmacology
Head-to-head clinical analysis: LOESTRIN FE 1 5 30 versus NYLIA 7 7 7.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOESTRIN FE 1 5 30 versus NYLIA 7 7 7.
LOESTRIN FE 1.5/30 vs NYLIA 7/7/7
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Suppresses gonadotropin (FSH and LH) release via estrogen and progestin feedback inhibition, preventing ovulation; increases cervical mucus viscosity and alters endometrial lining.
Combination of ethinyl estradiol and norethindrone; suppresses gonadotropin release, inhibiting ovulation and altering cervical mucus and endometrial lining.
One tablet orally once daily at the same time each day for 21 consecutive days, followed by 7 days of placebo (ferrous fumarate) tablets, then restart.
One tablet orally once daily, with each tablet containing 0.035 mg ethinyl estradiol and sequentially 0.5 mg, 0.75 mg, 1 mg norgestimate for days 1-7, 8-14, 15-21 respectively, followed by 7 placebo days.
None Documented
None Documented
Norethindrone: ~5-14 hours (terminal); Ethinyl estradiol: ~13-27 hours (terminal). Clinically, steady-state achieved within 5-7 days.
Terminal elimination half-life is 14 hours (range 10–18 hours). In renal impairment (CrCl <30 mL/min), half-life extends to 30–50 hours, necessitating dose adjustment.
Renal: ~50-60% (norethindrone metabolites); Fecal: ~20-30% (norethindrone); Ethinyl estradiol: primarily renal (~40-50%) and fecal (~20-50%) as glucuronide and sulfate conjugates.
Renal (70% as unchanged drug, 10% as active metabolite), fecal (15%), biliary (5%)
Category C
Category C
Combined Oral Contraceptive
Combined Oral Contraceptive